Jasper Therapeutics Files 8-K
Ticker: JSPRW · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $115.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-reporting
Related Tickers: JSPR
TL;DR
Jasper Therapeutics filed an 8-K on Jan 8, 2025. Standard reporting.
AI Summary
Jasper Therapeutics, Inc. filed an 8-K on January 8, 2025, reporting on other events and financial statements. The company, formerly known as Amplitude Healthcare Acquisition Corp. until September 12, 2019, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides an update on Jasper Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating any specific new risks.
Key Numbers
- 001-39138 — Commission File Number (Identifies the company's SEC filing history)
- 84-2984849 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — Registrant
- Amplitude Healthcare Acquisition Corp. (company) — Former company name
- January 8, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Jasper Therapeutics, Inc.?
The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of January 8, 2025.
When did Jasper Therapeutics, Inc. change its name from Amplitude Healthcare Acquisition Corp.?
The name change from Amplitude Healthcare Acquisition Corp. to Jasper Therapeutics, Inc. occurred on September 12, 2019.
In which state is Jasper Therapeutics, Inc. incorporated?
Jasper Therapeutics, Inc. is incorporated in Delaware.
What is the SIC code and industry classification for Jasper Therapeutics, Inc.?
The SIC code is 2836, and the industry classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the business address of Jasper Therapeutics, Inc.?
The business address is 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA 94065.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-08 07:05:29
Key Financial Figures
- $0.0001 — tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
- $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC
Filing Documents
- ea0227148-8k_jasper.htm (8-K) — 37KB
- ea022714801ex99-1_jasper.htm (EX-99.1) — 41KB
- ea022714801ex99-2_jasper.htm (EX-99.2) — 40KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- ex99-2_001.jpg (GRAPHIC) — 446KB
- ex99-2_002.jpg (GRAPHIC) — 863KB
- ex99-2_003.jpg (GRAPHIC) — 326KB
- ex99-2_004.jpg (GRAPHIC) — 388KB
- ex99-2_005.jpg (GRAPHIC) — 552KB
- ex99-2_006.jpg (GRAPHIC) — 593KB
- ex99-2_007.jpg (GRAPHIC) — 403KB
- ex99-2_008.jpg (GRAPHIC) — 401KB
- ex99-2_009.jpg (GRAPHIC) — 428KB
- ex99-2_010.jpg (GRAPHIC) — 379KB
- ex99-2_011.jpg (GRAPHIC) — 315KB
- ex99-2_012.jpg (GRAPHIC) — 369KB
- ex99-2_013.jpg (GRAPHIC) — 541KB
- ex99-2_014.jpg (GRAPHIC) — 531KB
- ex99-2_015.jpg (GRAPHIC) — 659KB
- ex99-2_016.jpg (GRAPHIC) — 374KB
- ex99-2_017.jpg (GRAPHIC) — 679KB
- ex99-2_018.jpg (GRAPHIC) — 792KB
- ex99-2_019.jpg (GRAPHIC) — 412KB
- ex99-2_020.jpg (GRAPHIC) — 658KB
- ex99-2_021.jpg (GRAPHIC) — 586KB
- ex99-2_022.jpg (GRAPHIC) — 386KB
- ex99-2_023.jpg (GRAPHIC) — 657KB
- ex99-2_024.jpg (GRAPHIC) — 488KB
- ex99-2_025.jpg (GRAPHIC) — 419KB
- ex99-2_026.jpg (GRAPHIC) — 72KB
- ex99-2_027.jpg (GRAPHIC) — 446KB
- 0001213900-25-001810.txt ( ) — 18497KB
- jspr-20250108.xsd (EX-101.SCH) — 4KB
- jspr-20250108_def.xml (EX-101.DEF) — 26KB
- jspr-20250108_lab.xml (EX-101.LAB) — 36KB
- jspr-20250108_pre.xml (EX-101.PRE) — 25KB
- ea0227148-8k_jasper_htm.xml (XML) — 6KB
01
Item 8.01. Other Events. On January 8, 2025, Jasper Therapeutics, Inc. (the "Company"), issued a press release reporting positive preliminary data from the Company's ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria and disclosing that the Company will hold a conference call and webinar at 8:00 am EST on January 8, 2025 to present the preliminary data from the BEACON Phase 1b/2a study. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the presentation to be used in connection with the conference call and webinar on January 8, 2025 is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Press Release, dated January 8, 2025 . 99.2 Presentation—Jasper Therapeutics: Preliminary BEACON Results, dated January 8, 2025 . 104 Cover Page Interactive Data File , formatted in Inline Extensible Business Reporting Language (iXBRL). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JASPER THERAPEUTICS, INC. Date: January 8, 2025 By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 2